Kemwell Biopharma Acquires Cirrus Pharmaceuticals Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Kemwell Biopharma Acquires Cirrus Pharmaceuticals Inc.



Kemwell Biopharma, a global bio/pharmaceutical contract services company headquartered in Bangalore, India, announced that it has acquired Cirrus Pharmaceuticals Inc., a contract development services company based in Research Triangle Park, N.C., USA.

Since its inception in 1997, Cirrus has developed expertise in inhalation, parenteral, transdermal, topical and liquid dosage forms. It also offers stand-alone analytical services including stability studies.

Kemwell’s corporate objective is to build a leading global bio/pharmaceutical contract services company, said Anurag Bagaria, chairman and MD of Kemwell in a press statement. Cirrus will complement the existing contract services offered by Kemwell with early stage innovative product development. Kemwell will now provide customers with a complete solution from early development in the US to commercial manufacturing in Kemwell’s EMA, FDA, and PMDA approved facilities in India and Sweden.”

Source: Kemwell Biopharma

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca

Click here